Inhibiting CNS resident memory T cells driving neuroinflammation
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
Project Summary Multiple sclerosis (MS) is a chronic, autoimmune-mediated disease of the central nervous system characterized by demyelination, axonal loss, and progressive disability. Experimental autoimmune encephalomyelitis (EAE) is an animal model which shares specific particularities with MS, has helped develop current disease modifying therapies (DMTs) used to treat MS patients and has been instrumental to understand mechanisms behind disease development and progression. While current disease modifying therapies have been beneficial to improve the health of MS patients, a significant proportion of them continue to experience relapses, and disease tend to worsen over time suggesting the inflammatory and autoimmune response could be sustained in the CNS. Memory CD4+T cells and B cells have been implicated in the pathogenesis of MS. While most memory T cells can be sampled in the blood because they circulate between lymphoid tissues, blood and non-lymphoid tissues; and their egress from lymphoid tissues and migration to the CNS can be stopped by DMTs, a small fraction of memory T cells called tissue resident memory T cells (TRM) have unique proprieties and resides in non- lymphoid tissues. T cells with TRM phenotype have been identified in the CSF and CNS of individual with from MS. We hypothesize that CNS CD4+ TRMs form a reservoir of autoreactive T cells in the CNS which sustains disease and is poorly targeted by disease modifying therapies directed against circulating T cells. Using a newly developed TRM dependent model of EAE and a targeted CRISPR screen, we will: 1) Identify molecular cues that inhibit TRM maintenance in the CNS during EAE, 2) Validate individually the effect of selected genes on TRM maintenance and EAE progression. Our approach is poised to identify novel inhibitory genes for TRM and therefore could provide the basis for the development of new MS therapies which could work independently or in conjunction with current DMTs. In addition, our findings will provide novel fundamental information regarding TRM and means to inhibit them.
Grant Summary
Inhibiting CNS resident memory T cells driving neuroinflammation is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $490K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $490K
2028-01-31
- 1Confirm your organization is eligible for Inhibiting CNS resident memory T cells driving neuroinflammation from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Inhibiting CNS resident memory T cells driving neuroinflammation: Frequently Asked Questions
Who is eligible for the Inhibiting CNS resident memory T cells driving neuroinflammation?
Inhibiting CNS resident memory T cells driving neuroinflammation is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Inhibiting CNS resident memory T cells driving neuroinflammation provide?
Inhibiting CNS resident memory T cells driving neuroinflammation provides up to $490K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Inhibiting CNS resident memory T cells driving neuroinflammation deadline?
Applications for Inhibiting CNS resident memory T cells driving neuroinflammation are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Inhibiting CNS resident memory T cells driving neuroinflammation?
To apply for Inhibiting CNS resident memory T cells driving neuroinflammation, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.